Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 24c
November 3, 2022 8:15 AM EDTIntra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.57), $0.24 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $71.9 million versus the consensus estimate of $65.88 million.
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
... More